Women on GLP-1 receptor agonist weight-loss drugs, like Ozempic and Mounjaro, report unexpected pregnancies, raising concerns for fetal development.

Women taking weight-loss drugs like Ozempic and Mounjaro, part of the GLP-1 receptor agonist class, have reported unexpected pregnancies, raising concerns over their potential impact on fetal development. These medications, used to treat type 2 diabetes and aid weight loss, have not been studied in pregnant individuals and were excluded from clinical trials. Experts recommend stopping these drugs two months before trying to conceive, as their makers, Novo Nordisk and Eli Lilly, are now collecting data from real-world use to assess their safety during pregnancy.

May 08, 2024
32 Articles